We recently published a list of Jim Cramer’s Latest Lightning Round: 7 Stocks in Focus. In this article, we are going to take ...

and the competing kits sold by Fluent, are designed to run on machines made by Illumina. In its deal announcement late Tuesday, Illumina said its sequencing platform would remain “open,” and ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

Consumables, such as sequencing kits for specific genomes, are the main revenue driver with over 70% revenue contribution. We expect strong consumables growth as customers transition to Illumina ...

Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

being held in Florida—where the DNA sequencing giant is set to unveil more details and demonstrations—and follows up on Illumina’s recent expansions into proteomics and single-cell analysis.

Illumina, Inc. engages ... The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services ...

Illumina and next-gen sequencing (NGS) are synonymous ... The product will be a kit, which will be distributed with substrates (slides), reagents, and a consumable holder. Users will go through ...